Locus suicide recombination actively occurs on the functionally rearranged IgH allele in B-cells from inflamed human lymphoid tissues.


Journal

PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074

Informations de publication

Date de publication:
06 2019
Historique:
received: 25 09 2018
accepted: 14 05 2019
revised: 26 06 2019
pubmed: 15 6 2019
medline: 7 11 2019
entrez: 15 6 2019
Statut: epublish

Résumé

B-cell activation yields abundant cell death in parallel to clonal amplification and remodeling of immunoglobulin (Ig) genes by activation-induced deaminase (AID). AID promotes affinity maturation of Ig variable regions and class switch recombination (CSR) in mature B lymphocytes. In the IgH locus, these processes are under control of the 3' regulatory region (3'RR) super-enhancer, a region demonstrated in the mouse to be both transcribed and itself targeted by AID-mediated recombination. Alternatively to CSR, IgH deletions joining Sμ to "like-switch" DNA repeats that flank the 3' super-enhancer can thus accomplish so-called "locus suicide recombination" (LSR) in mouse B-cells. Using an optimized LSR-seq high throughput method, we now show that AID-mediated LSR is evolutionarily conserved and also actively occurs in humans, providing an activation-induced cell death pathway in multiple conditions of B-cell activation. LSR either focuses on the functional IgH allele or is bi-allelic, and its signature is mainly detected when LSR is ongoing while it vanishes from fully differentiated plasma cells or from "resting" blood memory B-cells. Highly diversified breakpoints are distributed either within the upstream (3'RR1) or downstream (3'RR2) copies of the IgH 3' super-enhancer and all conditions activating CSR in vitro also seem to trigger LSR although TLR ligation appeared the most efficient. Molecular analysis of breakpoints and junctions confirms that LSR is AID-dependent and reveals junctional sequences somehow similar to CSR junctions but with increased usage of microhomologies.

Identifiants

pubmed: 31199803
doi: 10.1371/journal.pgen.1007721
pii: PGENETICS-D-18-01875
pmc: PMC6594652
doi:

Substances chimiques

Immunoglobulins 0
Receptors, Antigen, B-Cell 0
AICDA (activation-induced cytidine deaminase) EC 3.5.4.-
Cytidine Deaminase EC 3.5.4.5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007721

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Blood. 1988 Apr;71(4):1048-55
pubmed: 2451545
J Immunol. 2014 Apr 1;192(7):3091-100
pubmed: 24567530
Nat Commun. 2016 Feb 17;7:10730
pubmed: 26883548
Oncotarget. 2017 Feb 21;8(8):12929-12940
pubmed: 28088785
Nat Commun. 2015 May 11;6:7084
pubmed: 25959683
Nucleic Acids Res. 2017 Jun 2;45(10):5829-5837
pubmed: 28369649
J Immunol. 2009 Jun 15;182(12):7595-602
pubmed: 19494283
Cell. 1994 Jun 3;77(5):737-47
pubmed: 8205622
Cell Rep. 2015 Nov 3;13(5):1059-71
pubmed: 26565917
J Allergy Clin Immunol. 2018 Oct;142(4):1352-1355
pubmed: 29935221
Nat Immunol. 2010 Aug;11(8):681-8
pubmed: 20644574
Mol Cell. 2018 May 17;70(4):650-662.e8
pubmed: 29731414
Mol Cell. 2017 Aug 3;67(3):361-373.e4
pubmed: 28757211
J Exp Med. 2014 May 5;211(5):975-85
pubmed: 24752300
J Exp Med. 1997 Feb 3;185(3):563-71
pubmed: 9053456
Cell. 2011 Sep 30;147(1):95-106
pubmed: 21962510
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16508-12
pubmed: 18940926
Science. 2012 May 18;336(6083):931-4
pubmed: 22539552
Blood. 2010 Sep 16;116(11):1895-8
pubmed: 20538806
Nat Immunol. 2011 Jan;12(1):62-9
pubmed: 21113164
Nat Genet. 1996 Sep;14(1):15-6
pubmed: 8782813
J Immunol. 2017 May 15;198(10):4148-4155
pubmed: 28416601
J Exp Med. 1997 Sep 15;186(6):845-58
pubmed: 9294139
Eur J Immunol. 1997 Nov;27(11):2981-5
pubmed: 9394827
Nucleic Acids Res. 2014 Dec 1;42(21):13186-93
pubmed: 25378327
Nucleic Acids Res. 2016 Feb 29;44(4):1746-59
pubmed: 26792894
Adv Immunol. 2011;110:27-70
pubmed: 21762815
Science. 2017 Oct 13;358(6360):
pubmed: 28935768
Blood. 2004 May 15;103(10):3828-36
pubmed: 14962903
J Exp Med. 2013 Jul 29;210(8):1501-7
pubmed: 23825188
Immunity. 2001 Aug;15(2):187-99
pubmed: 11520455
Genes Dev. 2004 Jul 1;18(13):1618-29
pubmed: 15231739
Eur J Immunol. 1998 Oct;28(10):3048-56
pubmed: 9808173

Auteurs

Iman Dalloul (I)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

François Boyer (F)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Zeinab Dalloul (Z)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Amandine Pignarre (A)

INSERM U1236, Université de Rennes; EFS Bretagne, Rennes, France.

Gersende Caron (G)

INSERM U1236, Université de Rennes; EFS Bretagne, Rennes, France.

Thierry Fest (T)

INSERM U1236, Université de Rennes; EFS Bretagne, Rennes, France.

Fabrice Chatonnet (F)

INSERM U1236, Université de Rennes; EFS Bretagne, Rennes, France.

Céline Delaloy (C)

INSERM U1236, Université de Rennes; EFS Bretagne, Rennes, France.

Anne Durandy (A)

Institut Imagine INSERM U1163, Paris, France.

Robin Jeannet (R)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Emilie Lereclus (E)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Hend Boutouil (H)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Jean-Claude Aldigier (JC)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Sophie Péron (S)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Sandrine Le Noir (S)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.

Jeanne Cook-Moreau (J)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.
MC and JCM co-directed this work.

Michel Cogné (M)

CNRS UMR 7276 / INSERM U1262, Université de Limoges, Limoges, France.
INSERM U1236, Université de Rennes; EFS Bretagne, Rennes, France.
MC and JCM co-directed this work.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH